CLBS Stock Price, Chart, Stats & News
Caladrius Biosciences, Inc. (CLBS) does not currently pay a dividend.
CLBS chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | -10322.35% |
Net margin | -9756.47% |
Effective tax rate | 5.48% |
ROA | -93.47% |
ROE | -84.39% |
D/E | – |
Interest coverage ratio | – |
CLBS valuation
P/E | – |
P/S | 19.71x |
P/B | 0.25x |
P/CF | -0.23x |
P/FCF | -0.21x |
P/OCF | -0.23x |
PEG | -0.00x |
EV multiple | – |
About
Caladrius Biosciences, Inc. operates as a clinical-stage biopharmaceutical company primarily engaged in the development and commercialization of cellular therapies. These therapies aim to either reverse various diseases or stimulate the regeneration of compromised tissue. The company's pipeline includes several key investigational therapies: HONEDRA, which has received the prestigious SAKIGAKE designation, is undergoing Phase II clinical trials as a potential treatment for critical limb ischemia; XOWNA is currently in Phase IIb trials targeting coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy, is being evaluated for chronic kidney disease in patients prior to requiring dialysis.
Similar securities
Based on sector and market capitalization
